company background image
HRTX

Heron TherapeuticsNasdaqCM:HRTX Stock Report

Market Cap

US$1.3b

7D

1.7%

1Y

-18.8%

Updated

27 Sep, 2021

Data

Company Financials +
HRTX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health3/6
Dividends0/6

HRTX Overview

Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet medical needs.

Heron Therapeutics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Heron Therapeutics
Historical stock prices
Current Share PriceUS$12.36
52 Week HighUS$10.10
52 Week LowUS$22.40
Beta1.39
1 Month Change6.64%
3 Month Change-20.82%
1 Year Change-18.79%
3 Year Change-60.35%
5 Year Change-25.59%
Change since IPO-97.31%

Recent News & Updates

Shareholder Returns

HRTXUS BiotechsUS Market
7D1.7%-2.3%0.1%
1Y-18.8%26.0%35.3%

Return vs Industry: HRTX underperformed the US Biotechs industry which returned 26% over the past year.

Return vs Market: HRTX underperformed the US Market which returned 35.3% over the past year.

Price Volatility

Is HRTX's price volatile compared to industry and market?
HRTX volatility
HRTX Beta1.39
Industry Beta1.03
Market Beta1

Stable Share Price: HRTX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: HRTX's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1983223Barry Quarthttps://www.herontx.com

Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet medical needs. The company’s product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy.

Heron Therapeutics Fundamentals Summary

How do Heron Therapeutics's earnings and revenue compare to its market cap?
HRTX fundamental statistics
Market CapUS$1.26b
Earnings (TTM)-US$234.14m
Revenue (TTM)US$83.03m

15.2x

P/S Ratio

-5.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
HRTX income statement (TTM)
RevenueUS$83.03m
Cost of RevenueUS$206.08m
Gross Profit-US$123.04m
ExpensesUS$111.09m
Earnings-US$234.14m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-2.30
Gross Margin-148.19%
Net Profit Margin-281.99%
Debt/Equity Ratio93.0%

How did HRTX perform over the long term?

See historical performance and comparison

Valuation

Is Heron Therapeutics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: HRTX ($12.59) is trading below our estimate of fair value ($91.97)

Significantly Below Fair Value: HRTX is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: HRTX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: HRTX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate HRTX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: HRTX is overvalued based on its PB Ratio (8x) compared to the US Biotechs industry average (3.3x).


Future Growth

How is Heron Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

63.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: HRTX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: HRTX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: HRTX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: HRTX's revenue (40.4% per year) is forecast to grow faster than the US market (9.8% per year).

High Growth Revenue: HRTX's revenue (40.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if HRTX's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Heron Therapeutics performed over the past 5 years?

-6.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: HRTX is currently unprofitable.

Growing Profit Margin: HRTX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: HRTX is unprofitable, and losses have increased over the past 5 years at a rate of 6.6% per year.

Accelerating Growth: Unable to compare HRTX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: HRTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).


Return on Equity

High ROE: HRTX has a negative Return on Equity (-146.23%), as it is currently unprofitable.


Financial Health

How is Heron Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: HRTX's short term assets ($366.8M) exceed its short term liabilities ($82.1M).

Long Term Liabilities: HRTX's short term assets ($366.8M) exceed its long term liabilities ($162.0M).


Debt to Equity History and Analysis

Debt Level: HRTX's debt to equity ratio (93%) is considered high.

Reducing Debt: HRTX's debt to equity ratio has increased from 5.4% to 93% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: HRTX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if HRTX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Heron Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate HRTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate HRTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if HRTX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if HRTX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of HRTX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.7yrs

Average management tenure


CEO

Barry Quart (64 yo)

9.67yrs

Tenure

US$5,346,803

Compensation

Dr. Barry D. Quart, Pharm D., has been the Chief Executive Officer of Heron Therapeutics, Inc. since 2013 and has been its Director since 2013. Dr. Quart has been Chairman of Heron Therapeutics, Inc. since...


CEO Compensation Analysis

Compensation vs Market: Barry's total compensation ($USD5.35M) is above average for companies of similar size in the US market ($USD3.68M).

Compensation vs Earnings: Barry's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: HRTX's management team is considered experienced (4.7 years average tenure).


Board Members

Experienced Board: HRTX's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.2%.


Top Shareholders

Company Information

Heron Therapeutics, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Heron Therapeutics, Inc.
  • Ticker: HRTX
  • Exchange: NasdaqCM
  • Founded: 1983
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.260b
  • Shares outstanding: 101.91m
  • Website: https://www.herontx.com

Number of Employees


Location

  • Heron Therapeutics, Inc.
  • 4242 Campus Point Court
  • Suite 200
  • San Diego
  • California
  • 92121
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/27 22:53
End of Day Share Price2021/09/27 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.